
    
      This is an open-label, phase 1, dose-escalation trial evaluating the safety of TILT-123 as
      monotherapy in advanced solid tumor patients. TILT-123 is an oncolytic adenovirus coding for
      tumor necrosis factor alpha and interleukin 2. The trial includes 2 healthcare centers in
      Helsinki (Finland). Patients with different indications are expected to be treated in the
      trial.
    
  